- Home
- TOPS vs NRSN Comparison
TOPS vs NRSN Comparison
Compare TOPS & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- NRSN
- Stock Information
- Founded
- TOPS 2000
- NRSN 2017
- Country
- TOPS Greece
- NRSN Israel
- Employees
- TOPS N/A
- NRSN N/A
- Industry
- TOPS Marine Transportation
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- NRSN Health Care
- Exchange
- TOPS Nasdaq
- NRSN Nasdaq
- Market Cap
- TOPS 27.6M
- NRSN 26.0M
- IPO Year
- TOPS 2004
- NRSN 2021
- Fundamental
- Price
- TOPS $5.30
- NRSN $1.52
- Analyst Decision
- TOPS
- NRSN Buy
- Analyst Count
- TOPS 0
- NRSN 2
- Target Price
- TOPS N/A
- NRSN $14.00
- AVG Volume (30 Days)
- TOPS 6.6K
- NRSN 250.0K
- Earning Date
- TOPS 06-03-2025
- NRSN 06-23-2025
- Dividend Yield
- TOPS N/A
- NRSN N/A
- EPS Growth
- TOPS N/A
- NRSN N/A
- EPS
- TOPS 1.09
- NRSN N/A
- Revenue
- TOPS $86,127,000.00
- NRSN N/A
- Revenue This Year
- TOPS $9.90
- NRSN N/A
- Revenue Next Year
- TOPS N/A
- NRSN N/A
- P/E Ratio
- TOPS $4.87
- NRSN N/A
- Revenue Growth
- TOPS 3.83
- NRSN N/A
- 52 Week Low
- TOPS $5.12
- NRSN $0.51
- 52 Week High
- TOPS $14.24
- NRSN $1.63
- Technical
- Relative Strength Index (RSI)
- TOPS 33.93
- NRSN 69.91
- Support Level
- TOPS $5.11
- NRSN $1.22
- Resistance Level
- TOPS $5.97
- NRSN $1.63
- Average True Range (ATR)
- TOPS 0.20
- NRSN 0.14
- MACD
- TOPS -0.05
- NRSN 0.04
- Stochastic Oscillator
- TOPS 20.87
- NRSN 82.81
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.